Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine in Platinum Resistant or Refractory Ovarian Cancer
NCT00403429Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2006
- Primary completion
- Jan 2008
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine in ovarian cancer, sponsored by National Cancer Institute. Started Mar 2006; status: completed.
02
Drugs
capecitabine
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT00403429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00403429.